Stablecoin Development Corp

SDEV

Capitalización de mercado USD 44.6 M

Shares of Stablecoin Development Corporation (NYSE:SDEV) are surging on heavy trading volume Tuesday afternoon, despite no company-specific news for the session. Here's a closer look at what could be driving the sudden rally.

Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.

Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026  SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant liabilities from its balance sheet WEST PALM BEACH, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- Stablecoin Development Corporation (NYSE American: SDEV) (the “Company” or “SDEV”), an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems and providing public market access to the stablecoin economy, yesterday reported financial results for the second quarter and first half ended June 30, 2026.

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly NovaBay Pharmaceuticals, Inc.) who held their shares prior to August 19, 2025.

Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announced Monday its corporate name change to Stablecoin Development Corporation, signaling a full shift toward a cryptocurrency-focused strategy.

Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired  2.06 billion SKY tokens

EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards.

EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025.

EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025.